She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Health Canada has approved Novartis Canada’s Fabhalta (iptacopan capsules) as the first oral monotherapy to treat adults with ...

Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated i ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen dropped two antisense drugs in a pipeline cull and Voyager hit a setback for its ALS gene therapy.

Pfizer hopes a unique life-extension benefit for its Talzenna can serve to further expand the drug’s already ...

We think Biogen's neurology, immunology, and focus on rare diseases support a narrow moat. Biogen's strategy has its roots in the 2003 merger of Biogen (Avonex for treating multiple sclerosis, or MS) ...

Canada NewsWire MONTREAL, Feb. 13, 2025 MONTREAL, Feb. 13, 2025 /CNW/ - Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance for Fabhalta® ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

To boost its cardiovascular pipeline, Novartis has announced the acquisition of the company it co-founded with Blackstone ...

The candidate in question is VY9323, an AAV gene therapy combining a highly potent pri-miRNA against superoxide dismutase 1 ...